With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Areas of Expertise Biosimilars Generic Drugs Companies Legal Issues Intellectual Property Market Intelligence
Writes for Generics Bulletin
Latest From Aidan Fry
Pressure Mounts For German Tender Reforms
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Patent Settlements May Break EU Law
Patent-litigation settlements reached almost 20 years ago in the UK over GSK’s Seroxat paroxetine antidepressant may contravene EU competition law, an advocate general has advised the CJEU.
Alembic Aims To Build On Booming US Business
With its predominantly solid-dose portfolio in the US producing strong growth, India’s Alembic Pharmaceuticals is increasingly securing FDA clearance to push into differentiated dosage forms.
Coherus Is Confident After US Ranibizumab Filing
Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.
Viatris Will Tread A Different Path
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.